Table 1.

Demographic data stratified according to EF groups

General characteristics	EF ≥ 50%	EF < 50%	p value
	(n = 92)	(n = 72)
Age years	73 (67; 79)	58 (47; 64)	< 0.001
Female	57 (62%)	15 (21%)	< 0.001
Medical history and symptoms
AF	44 (48%)	33 (46%)	0.799
PM/CRT	8/0 (9%)	8/16 (33%)
Hypertension	63 (69%)	42 (58%)	0.30
Diabetes mellitus	17 (19%)	13 (18%)	0.84
Hypercholesterolaemia	22 (24%)	23 (32%)	0.197
Ischaemic heart disease	3 (3%)	19 (26%)	< 0.001
NYHA I	12 (13%)	1 (1%)
NYHA II	18 (20%)	9 (13%)
NYHA III	59 (64%)	56 (78%)
NYHA IV	3 (3%)	6 (8%)
Clinical measurements
BMI kg/m2	27 (23; 30)	27 (24; 31)	0.63
Obesity (BMI ≥ 30)	25 (27%)	19 (26%)	0.911
SBP (mm Hg)	130 (117; 142)	101 (93; 115)	< 0.001
DBP (mm Hg)	67 (60; 71)	62 (55; 70)	0.04
HR (beats/min)	70 (60; 80)	68 (59; 77)	0.51
Treatment
ARB or ACE-I	50 (54)	64 (89)	< 0.001
Loop diuretic	63 (69)	65 (90)	0.001
Beta blocker	61 (66)	68 (94)	< 0.001
MRA	30 (33%)	53 (74%)	< 0.001
Calcium channel blocker	26 (28)	5 (7)	= 0.001
Laboratory findings
NT-proBNP (ng/L)	1250 (365; 2300)	2580 (1265; 2693)	< 0.001
eGFR (mL/min/1.73 m2)	65 (46; 88)	81 (68; 102)	< 0.001
Hemoglobin (mg/L)	123 (113; 140)	138 (125; 148)	< 0.001

Categorical variables are provided as absolute numbers followed by percentages in brackets; continuous variables or median values followed by 1st and 3rd quartiles in brackets

EF ejection fraction, AF atrial fibrillation or flutter, PM pacemaker, CRT cardiac resynchonization therapy, NYHA New York Heart Association functional class, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, ARB angiotensin receptor blocker, ACE-I ACE-inhibitor, MRA mineralocorticoid receptor antagonist, NT-proBNP N-terminal pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate